Mankind Pharma to attend three investor conferences in September 2026

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Mankind Pharma management to attend three investor conferences in September 2026
  • Events include Jefferies 5th India Forum in Gurgaon and J.P. Morgan conference in Mumbai
  • Discussions restricted to public domain information and general business outlook
  • No unpublished price sensitive information will be shared during meetings
powered bylight_fuzz_icon
50665615

*this image is generated using AI for illustrative purposes only.

Mankind Pharma Limited announced its management will participate in three investor conferences scheduled for September 2026.

The company disclosed the engagements pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Schedule

The management officials will engage with investors and analysts through one-on-one or group meetings at the following events:

Date Event Name City
September 17, 2026 Jefferies 5th India Forum Gurgaon
September 18, 2026 Health care Forum Mumbai
September 21, 2026 J.P. Morgan India Conference Mumbai

Disclosure Guidelines

The company stated that no unpublished price sensitive information will be disclosed during these meetings. Discussions will be limited to general business outlook and information already available in the public domain.

The schedule remains subject to change due to exigencies on either side. The intimation has been uploaded on the company website.

Historical Stock Returns for Mankind Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+1.86%-3.75%-6.48%+1.89%-12.59%0.0%

How might Mankind Pharma's strategic messaging at these September 2026 conferences influence its stock valuation in the subsequent quarter?

What specific growth initiatives or pipeline developments is the company likely to highlight to differentiate itself from competitors at the Jefferies and J.P. Morgan forums?

Could the management's engagement with global analysts signal an impending expansion into new international markets or partnerships?

Mankind Pharma subsidiary Bharat Serums approved for voluntary liquidation

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Bharat Serums and Vaccines, a subsidiary of Mankind Pharma, has received approval for voluntary liquidation.
  • The liquidation process remains subject to pending creditor consent before it can be formally concluded.
powered bylight_fuzz_icon
50329227

*this image is generated using AI for illustrative purposes only.

Mankind Pharma 's subsidiary Bharat Serums and Vaccines has received approval for voluntary liquidation, with the process remaining subject to pending creditor consent.

Voluntary liquidation approval

Bharat Serums and Vaccines, a subsidiary of Mankind Pharma, has been granted approval to proceed with voluntary liquidation. The process is contingent on obtaining the requisite consent from creditors before it can be formally concluded.

Parameter Details
Company Bharat Serums and Vaccines
Parent Company Mankind Pharma
Development Voluntary liquidation approved
Condition Pending creditor consent

Historical Stock Returns for Mankind Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+1.86%-3.75%-6.48%+1.89%-12.59%0.0%

How will the voluntary liquidation of Bharat Serums and Vaccines impact Mankind Pharma's consolidated financial statements in the upcoming quarters?

What strategic rationale does Mankind Pharma have for winding down this subsidiary, and does it signal a broader shift away from the serums and vaccines segment?

Are there any potential legal or operational risks associated with obtaining creditor consent for the liquidation process?

More News on Mankind Pharma

1 Year Returns:-12.59%